JP2013501722A5 - - Google Patents

Download PDF

Info

Publication number
JP2013501722A5
JP2013501722A5 JP2012523949A JP2012523949A JP2013501722A5 JP 2013501722 A5 JP2013501722 A5 JP 2013501722A5 JP 2012523949 A JP2012523949 A JP 2012523949A JP 2012523949 A JP2012523949 A JP 2012523949A JP 2013501722 A5 JP2013501722 A5 JP 2013501722A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
compound
subject
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012523949A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013501722A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/044570 external-priority patent/WO2011017534A2/en
Publication of JP2013501722A publication Critical patent/JP2013501722A/ja
Publication of JP2013501722A5 publication Critical patent/JP2013501722A5/ja
Pending legal-status Critical Current

Links

JP2012523949A 2009-08-07 2010-08-05 前立腺癌の処置 Pending JP2013501722A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23225709P 2009-08-07 2009-08-07
US61/232,257 2009-08-07
US26126509P 2009-11-13 2009-11-13
US61/261,265 2009-11-13
PCT/US2010/044570 WO2011017534A2 (en) 2009-08-07 2010-08-05 Treatment of prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015221564A Division JP2016074687A (ja) 2009-08-07 2015-11-11 前立腺癌の処置

Publications (2)

Publication Number Publication Date
JP2013501722A JP2013501722A (ja) 2013-01-17
JP2013501722A5 true JP2013501722A5 (enExample) 2013-09-19

Family

ID=43535282

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012523949A Pending JP2013501722A (ja) 2009-08-07 2010-08-05 前立腺癌の処置
JP2015221564A Pending JP2016074687A (ja) 2009-08-07 2015-11-11 前立腺癌の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015221564A Pending JP2016074687A (ja) 2009-08-07 2015-11-11 前立腺癌の処置

Country Status (8)

Country Link
US (5) US8791094B2 (enExample)
EP (1) EP2461814A4 (enExample)
JP (2) JP2013501722A (enExample)
KR (1) KR20120056267A (enExample)
AU (1) AU2010279398A1 (enExample)
BR (1) BR112012002797A2 (enExample)
CA (1) CA2770092A1 (enExample)
WO (1) WO2011017534A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US8785423B2 (en) * 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2010149755A1 (en) 2009-06-26 2010-12-29 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
WO2011017534A2 (en) 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
EA023064B1 (ru) 2011-04-28 2016-04-29 Новартис Аг ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
CA2841960A1 (en) * 2011-07-18 2013-01-24 Tokai Pharmaceuticals, Inc. Novel compositions and methods for treating prostate cancer
AU2012294570B2 (en) * 2011-08-05 2015-09-10 Gen-Probe Incorporated Antiandrogen therapy monitoring methods and compositions
WO2013071177A1 (en) * 2011-11-10 2013-05-16 Tokai Pharmaceuticals, Inc. Methods and compositions for inhibition of androgen receptor activity
SG11201507093WA (en) 2013-03-14 2015-10-29 Univ Maryland Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
SG11201600525XA (en) 2013-08-12 2016-02-26 Tokai Pharmaceuticals Inc Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
WO2015170336A1 (en) 2014-05-09 2015-11-12 Council Of Scientific & Industrial Research 16α-HETEROARYL PREGNENOLONE ACETATE AND A PROCESS FOR PREPARATION THEREOF
WO2016119742A1 (zh) * 2015-01-29 2016-08-04 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法
ITUA20164043A1 (it) * 2016-06-01 2017-12-01 Ind Chimica Srl Processo per la preparazione di 3β-idrossi-17-(1H-benzimidazol-1-il)androsta-5,16-diene
ES2697706R1 (es) * 2016-06-01 2019-02-08 Ind Chimica Srl Proceso Para La Preparación De Galeterona.
AU2019287541A1 (en) * 2018-06-14 2021-01-21 Astrazeneca Uk Limited Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition
CN114072414A (zh) * 2019-04-27 2022-02-18 健康研究股份有限公司 用于治疗前列腺癌的香豆素修饰的雄激素

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621803A5 (enExample) * 1974-08-08 1981-02-27 Siphar Sa
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
NZ266640A (en) * 1993-04-30 1998-01-26 Pacific Northwest Research Fou Diagnosing genotoxic or carcinogenic status by analysing cellular redox potential where increased risk is indicated when the potential favours oxidatively derived modified nucleotides
US5994335A (en) * 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
US20030054053A1 (en) * 2001-09-20 2003-03-20 Charles Young Methods and compositions for inhibiting the proliferation of prostate cancer cells
ES2369487T3 (es) 2003-07-29 2011-12-01 Dompe' S.P.A. Combinación farmacéutica de g-csf y plgf útil para células madre de sangre.
JP4585201B2 (ja) * 2004-01-23 2010-11-24 丸善製薬株式会社 アンドロゲン受容体結合阻害剤、養毛剤、皮脂分泌抑制剤及び前立腺肥大抑制剤
DK2206719T3 (en) * 2005-03-02 2015-01-26 Univ Maryland A pharmaceutical composition comprising 3-BETA-HYDROXY-17- (1-H-benzimidazol-1-yl) androsta-5, 16-DIEN
WO2008154382A1 (en) 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
US20100048913A1 (en) * 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2011017534A2 (en) 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer

Similar Documents

Publication Publication Date Title
JP2013501722A5 (enExample)
JP2013510856A5 (enExample)
JP2015527360A5 (enExample)
AU2012330885B2 (en) Oral immediate release formulations for substituted quinazolinones
JP2011068653A5 (enExample)
CN115667238A (zh) 一种五并五元环衍生物及其在医药上的应用
TWI598098B (zh) 脂質異常症治療劑
JP2017057230A5 (enExample)
JP2014532638A5 (enExample)
CN1379669A (zh) 维得克西组合物
JP2012516900A5 (enExample)
JP2012255026A5 (enExample)
JP2016522835A5 (enExample)
KR20140075754A (ko) 7-[4-(4-벤조[ｂ]티오펜-4-일-피페라진-1-일)부톡시]-1Ｈ-퀴놀린-2-온 또는 그 염을 함유하는 정제
TW200538115A (en) New pharmaceutical compositions for the treatment of sexual disorders
IL314360B2 (en) Method for the synthesis of thyroid hormone analogs and their polymorphs
EA200901277A1 (ru) Фармацевтические составы, содержащие пропиленгликольгидрат дапаглифлозина
JP2014508752A5 (enExample)
JP2019516684A5 (enExample)
JP2016515628A5 (enExample)
CN105848656A (zh) 药物组合
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
CN111315378A (zh) 包含lsz102和瑞博西尼的药物组合
US12396969B2 (en) Compounds and methods for the treatment of parasitic infections
FR3056108B1 (fr) Utilisation des harringtonines dans le traitement cancer du sein, notamment triple-negatif